Skip to main content

NUEVOS AVANCES EN EL ESTUDIO DE LA VIA DE RANK EN CANCER DE MAMA: DE LA BIOLOGIA AL TRATAMIENTO

SAF2017-86117-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness.

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S
  • Collado-Solé, Alejandro
  • Jimenez, Maria
  • Sanz-Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C
  • De Benedictis, Ilaria
  • Gómez-Aleza, Clara
  • Da Silva-Álvarez, Sabela
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • Gonzalez-Suarez, Eva
  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S
  • Collado-Solé, Alejandro
  • Jimenez, Maria
  • Sanz-Moreno, Adrian
  • Yoldi, Guillermo
  • Santos, Juliana C
  • De Benedictis, Ilaria
  • Gómez-Aleza, Clara
  • Da Silva-Álvarez, Sabela
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcazar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • Gonzalez-Suarez, Eva
Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
Repisalud
Publication Artículo científico (JournalArticle)

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

  • Sanz-Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomas
  • Galván, Patricia
  • Benítez, Sandra
  • Gomez-Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, Maria
  • Pernas, Sonia
  • Petit, Anna
  • Soler-Monsó, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A
  • Green, Andrew R
  • Santamaria, Patricia G
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquin
  • Prat, Aleix
  • Puig, Teresa
  • Gonzalez-Suarez, Eva
  • Sanz-Moreno, Adrián
  • Palomeras, Sonia
  • Pedersen, Kim
  • Morancho, Beatriz
  • Pascual, Tomas
  • Galván, Patricia
  • Benítez, Sandra
  • Gomez-Miragaya, Jorge
  • Ciscar, Marina
  • Jimenez, Maria
  • Pernas, Sonia
  • Petit, Anna
  • Soler-Monsó, María Teresa
  • Viñas, Gemma
  • Alsaleem, Mansour
  • Rakha, Emad A
  • Green, Andrew R
  • Santamaria, Patricia G
  • Mulder, Celine
  • Lemeer, Simone
  • Arribas, Joaquin
  • Prat, Aleix
  • Puig, Teresa
  • Gonzalez-Suarez, Eva
Around 15-20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive breast cancer and anti-HER2 therapy resistance.
Repisalud
Publication Artículo científico (JournalArticle)

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

  • Ciscar, Marina
  • Trinidad, Eva M
  • Perez-Chacon, Gema
  • Alsaleem, Mansour
  • Jimenez, Maria
  • Jimenez-Santos, Maria J
  • Perez-Montoyo, Hector
  • Sanz-Moreno, Adrian
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, Maria T
  • Lopez, Victor
  • Gomez-Miragaya, Jorge
  • Gomez-Aleza, Clara
  • Dobrolecki, Lacey E
  • Lewis, Michael T
  • Bruna, Alejandra
  • Mouron, Silvana
  • Al-Shahrour, Fatima
  • Quintela Fandino, Miguel Angel
  • Martinez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R
  • Rakha, Emad
  • Gonzalez-Suarez, Eva
  • Ciscar, Marina
  • Trinidad, Eva M
  • Perez-Chacon, Gema
  • Alsaleem, Mansour
  • Jimenez, Maria
  • Jimenez-Santos, Maria J
  • Perez-Montoyo, Hector
  • Sanz-Moreno, Adrian
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, Maria T
  • Lopez, Victor
  • Gomez-Miragaya, Jorge
  • Gomez-Aleza, Clara
  • Dobrolecki, Lacey E
  • Lewis, Michael T
  • Bruna, Alejandra
  • Mouron, Silvana
  • Martinez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R
  • Rakha, Emad
  • Gonzalez-Suarez, Eva
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor-negative, ER ) from four independent cohorts. RANK protein expression was more frequent in ER tumors, where it associated with poor outcome and poor response to chemotherapy. In ER breast cancer patient-derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK ER tumors after menopause.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness

  • Benítez, Sandra
  • Cordero, Alex
  • Santamaría, Patricia G.
  • Redondo-Pedraza, Jaime
  • Rocha, Ana S.
  • Collado-Solé, Alejandro
  • Jiménez, María
  • Sanz-Moreno, Adrián
  • Yoldi, Guillermo
  • Santos, Juliana C.
  • Benedictis, Ilaria De
  • Gómez-Aleza, Clara
  • Silva-Alvarez, S. da
  • Troulé, Kevin
  • Gómez-López, Gonzalo
  • Alcázar, Noelia
  • Palmero, Ignacio
  • Collado, Manuel
  • Serrano, Manuel
  • González-Suarez, Eva
© 2021 The Authors., Rank signaling enhances stemness in mouse and human mammary epithelial cells (MECs) and mediates mammary tumor initiation. Mammary tumors initiated by oncogenes or carcinogen exposure display high levels of Rank and Rank pathway inhibitors have emerged as a new strategy for breast cancer prevention and treatment. Here, we show that ectopic Rank expression in the mammary epithelia unexpectedly delays tumor onset and reduces tumor incidence in the oncogene-driven Neu and PyMT models. Mechanistically, we have found that ectopic expression of Rank or exposure to Rankl induces senescence, even in the absence of other oncogenic mutations. Rank leads to DNA damage and senescence through p16/p19. Moreover, RANK-induced senescence is essential for Rank-driven stemness, and although initially translates into delayed tumor growth, eventually promotes tumor progression and metastasis. We uncover a dual role for Rank in the mammary epithelia: Rank induces senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness., This work was supported by grants to E. González-Suárez by the Agencia Estatal de Investigación (AEI) (SAF2014-55997-R, SAF2017-86117-R) co-funded by FEDER funds/European Regional Development Fund (ERDF) (a way to build Europe), by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 682935), and by the Fundació La Marató de TV3. We thank CERCA Programme/Generalitat de Catalunya for institutional support. S. Benítez was a recipient of an FPI, A. Collado-Solé holds an FPU from the MICINN and J Redondo-Pedraza is a recipient of an FPI Severo Ochoa Fellowship. We are grateful to Amgen for providing Rankl and Rankt+/tg mice.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

  • Ciscar, Marina
  • Trinidad, Eva M.
  • Pérez-Chacón, Gema
  • Alsaleem, Mansour
  • Jiménez, María
  • Jiménez-Santos, María J.
  • Pérez-Montoyo, Héctor
  • Sanz-Moreno, Adrián
  • Vethencourt, Andrea
  • Toss, Michael
  • Petit, Anna
  • Soler-Monso, María T.
  • López, Victor
  • Gómez-Miragaya, Jorge
  • Gómez-Aleza, Clara
  • Dobrolecki, Lacey E.
  • Lewis, Michael T.
  • Bruna, Alejandra
  • Mouron, Silvana
  • Quintela-Fandino, Miguel
  • Al-Shahrour, Fátima
  • Martínez-Aranda, Antonio
  • Sierra, Angels
  • Green, Andrew R.
  • Rakha, Emad
  • González-Suarez, Eva
Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL protein expression in more than 2,000 breast tumors (777 estrogen receptor‐negative, ER−) from four independent cohorts. RANK protein expression was more frequent in ER− tumors, where it associated with poor outcome and poor response to chemotherapy. In ER− breast cancer patient‐derived orthoxenografts (PDXs), RANKL inhibition reduced tumor cell proliferation and stemness, regulated tumor immunity and metabolism, and improved response to chemotherapy. Intriguingly, tumor RANK protein expression associated with poor prognosis in postmenopausal breast cancer patients, activation of NFKB signaling, and modulation of immune and metabolic pathways, suggesting that RANK signaling increases after menopause. Our results demonstrate that RANK protein expression is an independent biomarker of poor prognosis in postmenopausal and ER− breast cancer patients and support the therapeutic benefit of RANK pathway inhibitors, such as denosumab, in breast cancer patients with RANK+ ER− tumors after menopause., We thank Miguel Angel Pujana,Christian Tebe and Judith Pe~nafiel for the analyses of theIDBandCNIOcohorts, Sergi Velasco and Purificaci on Mu~noz for feedback about the manu-script. Work in the laboratory of EG-S has received funding from the SpanishMinisterio de Ciencia, Innovaci on y Universidades, which is part of AgenciaEstatal de Investigaci on (AEI) (SAF2014-55997-R, SAF2017-86117-R, andPID2020-116441GB-I00), the ISCIII (PIE13/00022) co-funded by EuropeanRegional Development Fund, a Career Catalyst Grant from the Susan KomenFoundation (CCR13262449), the Catalan Government2017SGR00665, co-funded by FEDER funds/European Regional Development Fund (ERDF) (a wayto build Europe), the European Research Council (ERC) under the EuropeanUnion’s Horizon2020research and innovation program (grant agreement no.682935), This study has been partially funded by Amgen Inc. EMT had receiveda Juan de la Cierva-Incorporaci on grant from Spanish Ministry of Science andInnovation (IJCI-2017-31564) and MG a PERIS contract from the Departamentof Salut de la Generalitat de Catalunya. The IDIBELL samples collection wasgranted by the Spanish Ministry of Health and Consumer Affairs FIS-PI14/00336from the I+D+I National Plan with the financial support from ISCIII-Subdirecci on General de Evaluaci on and the Fondo Europeo de DesarrolloRegional (FEDER). The generation of PDX models in the Lewis laboratory wassupported in part by NIH/NCI grants U54CA224076(MTL), U24CA226110(toMTL), P50CA186784(MTL) (Dan L. Duncan Cancer Center). This work was alsosupported by a Core Facility grant from the Cancer Prevention and ResearchInstitute of Texas (CPRIT Core Facilities Support Grant RP170691), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis

  • Collado-Sole, Alejandro
  • Borjini, Nozha
  • Zhai, Jing
  • Ruiz-Pino, Francisco
  • Soria-Alcaide, Gonzalo
  • Folgueira, Cintia
  • García-Vilela, Celia
  • Romero-de la Rosa, Beatriz
  • López, Víctor
  • Zouaghi, Yassine
  • Jacobs, An
  • Mora-Romero, Bella
  • Barranco, Alexandra
  • Yoldi, Guillermo
  • Rizzoti, Karine
  • Sabio, Guadalupe
  • Pérez-Chacón, Gema
  • Santamaría, Patricia G.
  • Esteban, José Antonio
  • Journiac, Nathalie
  • Prevot, Vincent
  • Pascual Bravo, Alberto
  • Fernández-Chacón, Rafael
  • Tena-Sempere, Manuel
  • Pitteloud, Nelly
  • González-Suárez, Eva
[Data, code, and materials availability] The scRNA-seq results obtained in this work have been deposited at Gene Expression Omnibus, GSE240379. Mouse strains used in this study are subject to a Material Transfer Agreement and can be shared upon reasonable request and in accordance with the corresponding institutional regulations. The rest of the data used in the preparation of the manuscript are available in the main text or in the supplementary materials., The hypothalamic-pituitary-gonadal axis (HPG) controls pubertal development, sexual maturation, and fertility. We identified a role of hypothalamic microglia in controlling the HPG axis through receptor activator of nuclear factor κB (Rank) signaling. Whole-body and microglia Rank (mouse) depletion led to hypogonadotropic hypogonadism (HH) resulting from an alteration in gonadotropin-releasing hormone (GnRH) neuron function. In addition, we identified rare gene variants of RANK (human) in patients with HH. Transcriptional profiling upon Rank loss revealed defective microglia activation and morphological alterations in the median eminence, decreasing the contacts and engulfment of GnRH terminal projections and impairing GnRH neuronal responses to kisspeptin. Overall, our data uncover the microglia as regulator of GnRH neuronal function through Rank signaling, with potential implications for reproductive maturation and fertility., This work was supported by grants from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 682935, EGS); CaixaResearch Health 2023 grants from the “la Caixa” Foundation (no. HR23-00361, EGS); Comunidad Autónoma de Madrid S2022/BMD-7393 (EGS) and the Spanish Ministry of Science and Innovation through the Agencia Estatal de Investigación (AEI) (SAF2017-86117-R, PID2020-116441GB-I00, and PID2023-152798OB-I00; EGS), cofunded by FEDER/European Regional Development Fund (ERDF) (“A way to build Europe”). Grant PID2023-149244NB-I00 was awarded to M.T.-S. Additional support was provided by the Spanish Agencia Estatal de Investigación and the Ministerio de Ciencia, Innovación y Universidades, and the European Regional Development Fund (ERDF) (MICIU/AEI/10.13039/501100011033; FEDER, UE) through project PID2022-138957NB-I00 (R.F.-C.) as well as by the Plan Propio de Investigación de la Universidad de Sevilla, Contrato Acción II.4 PPIT (N.B.). A.C.-S. was supported by an FPU fellowship (FPU2018/00546), and A.B. was supported by an FPI fellowship (PRE2018-086522). C.F. was supported by a Miguel Servet contract (CP24_00036) from the Instituto de Salud Carlos III (ISCIII). A.C.-S. also received an EACR travel grant (EACR-907), Peer reviewed